An oral G protein-coupled receptor 40 (GPR40) agonist demonstrated robust glycemic efficacy in adults with early type 2 diabetes mellitus (T2DM) managed with lifestyle therapy alone. A phase 2, double-blind, randomized, placebo-controlled trial published in Diabetes & Metabolism Journal evaluated the efficacy and safety of HD-6277 in individuals with inadequately controlled T2DM despite diet and exercise.

The study enrolled 112 adults aged 18 to 75 years with baseline glycosylated hemoglobin levels between 7.0% and 10.0% after at least 8 weeks of lifestyle intervention. Participants were randomized to receive HD-6277 at 50 mg, HD-6277 at 100 mg, or placebo for 12 weeks. Glycemic parameters were assessed at weeks 4, 8, and 12.

At week 12, both HD-6277 doses significantly reduced HbA1c compared with placebo. The least square mean difference was −0.73% (95% confidence interval [CI], −1.11 to −0.35; P=0.0002) with 50 mg and −0.85% (95% CI, −1.21 to −0.50; P<0.0001) with 100 mg. Fasting plasma glucose also declined significantly in both treatment groups.

Early-phase insulin secretion improved with the higher dose. HD-6277 at 100 mg increased the insulinogenic index compared with placebo, with a least square mean difference of 1.91 (95% CI, 0.34 to 3.48; P=0.0175). No clinically relevant treatment-related adverse events were observed, indicating a favorable short-term safety profile.

These findings support HD-6277 as an effective and well-tolerated oral therapy that improves glycemic control and beta-cell functional response in early T2DM managed without pharmacotherapy. The results reinforce GPR40 agonism as a mechanistically targeted therapeutic approach in the early disease course.